



CBSA SPOTLIGHT REVIEW: Vol. I No. X 19 April – 25 April

Company Spotlight

- **Allos Therapeutics** (Westminster) has completed patient enrollment a quarter ahead of schedule for their Phase II trial of PDX (pralatrexate) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). PDX is a novel, small molecule chemotherapeutic agent that inhibits dihydrofolate reductase, or DHFR, a folic acid (folate)-dependent enzyme involved in the building of nucleic acid, or DNA, and other processes. PDX was rationally designed for efficient transport into tumor cells via the reduced folate carrier, or RFC-1, and effective intracellular drug retention. Allos believes these biochemical features, together with preclinical and clinical data in a variety of tumors, suggest that PDX may have a favorable safety and efficacy profile relative to methotrexate and other related DHFR inhibitors and, has the potential to be delivered as a single agent or in combination therapy regimens.
- **Replidyne** (Louisville) terminated trial enrollment to preserve its \$78M cash position. The Acute Exacerbation of Chronic Bronchitis study that has been halted is one in a package of four clinical trials, including two in community-acquired pneumonia and one in acute bacterial sinusitis, recommended as a way forward by the FDA for a new drug application submission for faropenem to treat these three adult community respiratory tract infections. Replidyne has not initiated the other three trials, and consistent with prior guidance, further faropenem development will depend on the securing a partner for the program.

Financing

- **Evolutionary Genomics** (Lafayette) an agricultural technology company who addresses the critical need to increase the availability of biofuel feedstocks has closed an undisclosed Series A financing with Denver-based Altira Group.

People

- After serving as Interim Director of Fitzsimons BioBusiness Partners (FBBp) since January 2007, **Rick Silva, Ph.D., MBA** announced that he will vacate his post 31 August 2008. Dr. Silva has concurrently served as Director of the Office of Technology Transfer for the University of Colorado, Denver and will remain in that role. Prior to the responsibility of Interim Director Dr. Silva served as a founding Board member of FBBp and will return to that position. The CBSA has enjoyed a great working relationship with Rick and he will be missed in his FBBp role.

Square Pegs

- Lest you think the Colorado Bioscience Association merely flexes its muscle in Colorado...think again. The CBSA weighed in with significant support on Capitol Hill re: HR5819 or the **SBIR/STTR Reauthorization Act**, which passed in the U.S. House of Representatives by a vote of 369 to 43.

- **BioBeers** is locked and loaded for **Tuesday 29 April** at our new start time of **6:00pm** to be held at the **Vine St. Pub, 1700 Vine St. Denver 80206**. For more information and to RSVP please visit <http://BioBeers.com>.

Advance Colorado Center • 1625 Broadway Suite 950 • Denver Colorado 80202
Phone: 303-592-4073 • Fax: 303-592-4081 • www.CoBioScience.com